The AABB (formerly, the American Association of Blood Banks) developed this guideline on appropriate use of platelet transfusion in adult patients.
A pproximately 2.2 million platelet doses are transfused annually in the United States (1) . A high proportion of these platelet units are transfused prophylactically to reduce the risk for spontaneous bleeding in patients who are thrombocytopenic after chemotherapy or hematopoietic progenitor cell transplantation (HPCT) (1) (2) (3) . Unlike other blood components, platelets must be stored at room temperature, limiting the shelf life of platelet units to only 5 days because of the risk for bacterial growth during storage. Therefore, maintaining hospital platelet inventories is logistically difficult and highly resource-intensive (4, 5) . Platelet transfusion is associated with several risks to the recipient (Table 1) , including allergic reactions and febrile nonhemolytic reactions. Sepsis from a bacterially contaminated platelet unit represents the most frequent infectious complication from any blood product today (8) . In any situation where platelet transfusion is being considered, these risks must be balanced against the potential clinical benefits.
GUIDELINE FOCUS
These guidelines were designed to provide pragmatic recommendations, based on the best available published evidence, about when platelet transfusion may be appropriate in adult patients. For several common clinical situations, we attempted to identify a platelet count threshold below which platelet transfusion may improve hemostasis and above which platelet transfusion is unlikely to benefit the patient. We did not attempt to address all clinical situations in which platelets may be transfused, and these guidelines are not intended to serve as standards. Clinical judgment, and not a specific platelet count threshold, is paramount in deciding whether to transfuse platelets.
TARGET POPULATION
These guidelines provide advice for adult patients who are candidates for platelet transfusion.
GUIDELINE DEVELOPMENT PROCESS
The AABB commissioned and funded the development of these guidelines.
Panel Composition
A panel of 21 experts was convened. Fifteen participants were members of the Clinical Transfusion Medicine Committee of the AABB, all of whom were
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hematologists or pathologists with expertise in transfusion medicine. Five additional panel members included a neurosurgeon, a cardiac surgeon, a critical care specialist, an anesthesiologist, and a hematologist, representing the American Association of Neurological Surgeons, the Society of Thoracic Surgeons, the Society of Critical Care Medicine, the American Society of Anesthesiologists, and the American Society of Hematology, respectively. The final panel member was a Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodologist. Committee members had no substantial conflicts of interest as defined by the AABB conflict of interest policy. Pursuant to the policy, individual members were required to disclose actual and apparent financial, professional, or personal conflicts (Appendix Table 1 , available at www.annals .org).
Systematic Review of the Evidence
The guidelines were developed on the basis of a recent systematic review of the literature on platelet transfusions, published separately (11) . The search strategy is provided in Appendix Table 2 (available at www.annals.org). We searched PubMed from 1946 to the first week of April 2013, and the Cochrane Central Register of Controlled Trials and Web of Science from 1900 to the first week of April 2013 (1024 studies identified). An updated search of these databases was done from the first week of April 2013 to the first week of September 2014. Randomized, controlled trials (RCTs) and observational studies (prospective or retrospective cohort studies, case-control studies, and those with no control group) were eligible for inclusion. Outcomes of interest included all-cause mortality, bleeding-related mortality, bleeding, and number of platelet units transfused. Although all observational studies meeting the inclusion criteria were reviewed, data from observational studies were not used when more than 2 RCTs addressed a particular question. There were no language restrictions. After exclusions, 17 RCTs and 53 observational studies were included in the final systematic review. Only 1 relevant observational study (12) from the updated search was identified, and evidence from this study did not change our GRADE judgments of evidence quality or recommendation strength.
Grading of Evidence
The GRADE method was used to assess the quality of the evidence and determine the strength of recommendations (13, 14) . The recommendations were developed by consensus at an in-person panel meeting. Panel member judgments on 4 GRADE factors (quality of evidence, balance between the intervention's benefits and harms, resource use, and patient values and preferences) and ratings of the strength of recommendations were validated using an online survey tool 1 week after the meeting.
Definitions
In this guideline, a platelet unit refers to 1 apheresis platelet unit or a pool of 4 to 6 whole blood-derived platelet concentrates, typically containing 3 to 4 × 10 11 platelets. Thrombocytopenia refers to a platelet count below the lower limit of the normal range used by the laboratory performing the count. Seven platelet trials included in the systematic review (15-21) used a variation of the World Health Organization scale (22) to assess patient bleeding outcomes (23). A summary of the modified World Health Organization scale is provided in Table 2 .
CLINICAL RECOMMENDATIONS Clinical Setting 1: Hospitalized Adult Patients With Therapy-Induced Hypoproliferative Thrombocytopenia
Recommendations
Recommendation 1: The AABB recommends that platelets should be transfused prophylactically to reduce the risk for spontaneous bleeding in adult patients with therapy-induced hypoproliferative thrombocytopenia.
The AABB recommends transfusing hospitalized adult patients with a platelet count of 10 × 10 9 cells/L or less to reduce the risk for spontaneous bleeding.
The AABB recommends transfusing up to a single apheresis unit or equivalent. Greater doses are not more effective, and lower doses equal to one half of a standard apheresis unit are equally effective.
Quality of evidence: moderate; strength of recommendation: strong.
Evidence Summary
Three RCTs (n = 1047) compared bleeding outcomes in hospitalized patients with radiation and/or chemotherapy-induced hypoproliferative thrombocytopenia assigned to receive or not receive prophylactic platelet transfusions (Appendix Table 3 , available at www.annals.org) (19, 21, 24, 25) . All patients had hematologic malignancy treated with chemotherapy or HPCT. Prophylactic platelet transfusions were found to significantly reduce the risk for spontaneous grade 2 or greater bleeding (odds ratio [OR] , 0.53 [95% CI, 0.32 to 0.87]). Most bleeding events were classified as grade 2. In the 2 largest trials (19, 21) , grade 2 or greater bleeding in patients assigned to the group that did not receive prophylaxis occurred more frequently among pa- [19, 25] ; 51% vs. 28% [21] ).
The threshold platelet count at which platelets should be transfused prophylactically to reduce the bleeding risk in hospitalized patients with therapyinduced hypoproliferative thrombocytopenia was examined in 4 RCTs (n = 658) (Appendix Table 4 The total number of days with bleeding was greater in the 10 × 10 9 -cells/L threshold group. The 10 × 10 9 -cells/L threshold was associated with lower platelet usage and fewer transfusion reactions.
Four RCTs (n = 1132) (Appendix Table 5 , available at www.annals.org) examined whether prophylactic transfusion of low-dose platelets (defined as approximately one half of the standard dose of 3 to 4 × 10 11 platelets) would provide hemostasis equal to that of standard-dose platelets in patients with therapyinduced hypoproliferative thrombocytopenia (16, 18, 20, 29 
Rationale for Recommendations
Before routine platelet prophylaxis was introduced, severe hemorrhage was a common cause of death among patients receiving high-dose chemotherapy (30, 31). Today, severe hemorrhage is rarely encountered in this setting. The original studies of platelet prophylaxis were done decades ago, and both chemotherapy and supportive care for patients with cancer have changed dramatically over time. Therefore, the randomized trials reported by Wandt (21) and Stanworth (19) and their colleagues were designed to answer the question of whether a prophylactic as compared with a therapeutic platelet transfusion strategy provides benefit in contemporary cancer care. In the study by Wandt and colleagues (21) , grade 2 or greater bleeding was seen in 42% of patients assigned to receive therapeutic platelet transfusions only, compared with 19% of patients assigned to receive prophylactic platelet transfusion for a platelet count of 10 × 10 9 cells/L or less (P < 0.001). In the subset of patients with acute myelogenous leukemia, intracerebral bleeding (grade 4) occurred significantly more often in the therapeutic platelet group compared with the prophylactic platelet group (7% vs. 2%; P = 0.010). In 11 of 13 cases, intracerebral bleeding was detectable on CT scan, but there were no apparent clinical sequelae. Computed tomography scans to investigate new headache or other cerebral symptoms were required only for patients in the therapeutic platelet group, so subclinical intracerebral hemorrhage in the prophylactic platelet group may have been underdiagnosed. In the Trial of Prophylactic Platelets (19) , subtler differences in bleeding outcomes were seen between the study groups. Grade 2 or greater bleeding occurred in 50% of patients assigned to the group that did not receive prophylaxis, compared with 43% of patients receiving prophylactic platelet transfusions (P = 0.06 for noninferiority). In patients receiving chemotherapy (not HPCT), there was a significant increase in grade 2 or greater bleeding in the group that did not receive prophylaxis (risk difference, 20% [90% CI, 7.9% to 32.2%]). There was also a nonsignificant trend toward increased grade 3 and 4 bleeding for all patients in the group that did not receive prophylaxis. Thus, both the Wandt trial and the Trial of Prophylactic Platelets support the continued use of prophylactic platelet transfusions in patients with therapy-induced hypoproliferative thrombocytopenia. In this population, we recommend prophylactic platelet transfusion for a morning platelet count of 10 × 10 9 cells/L or less. Some data suggest that the risk for spontaneous bleeding does not increase until the platelet count decreases to less than approximately 6 × 10 9 cells/L (18, 32), but the 10 × 10 9 -cells/L platelet count Platelet Transfusion: A Clinical Practice Guideline From the AABB CLINICAL GUIDELINE threshold seems to provide a good balance of safety and practicality, and the accuracy of extremely low platelet count measurements is questionable (33, 34). The recommendation for prophylactic platelet transfusion based on a 10 × 10 9 -cells/L platelet count threshold applies to hospitalized patients only. Prophylactic platelet transfusion based on a more liberal (greater) platelet count threshold may be appropriate when treating outpatients, for reasons of practicality (fewer clinic visits).
The Platelet Dose study (18) established that patients receiving low-dose prophylactic platelet transfusions for a morning platelet count of 10 × 10 9 cells/L or less had the same bleeding risk as patients receiving standard-or high-dose platelets. However, low-dose platelets did need to be transfused more often because they provided a lower increment. It is safe to provide low-dose platelet prophylaxis to patients with therapyinduced hypoproliferative thrombocytopenia, either routinely or as a temporary maneuver in times of platelet shortage. High-dose prophylactic platelet transfusions have not been shown to provide additional benefit, so they are not recommended as routine therapy for inpatients.
Clinical Setting 2: Adult Patients Having Minor Invasive Procedures
Recommendations
Recommendation 2: The AABB suggests prophylactic platelet transfusion for patients having elective central venous catheter placement with a platelet count less than 20 × 10 9 cells/L. Quality of evidence: low; strength of recommendation: weak.
Recommendation 3: The AABB suggests prophylactic platelet transfusion for patients having elective diagnostic lumbar puncture with a platelet count less than 50 × 10 9 cells/L. Quality of evidence: very low; strength of recommendation: weak.
Evidence Summary
Eight observational studies of central venous catheter (CVC) placement in the setting of thrombocytopenia were identified (n = 1311 cannulations) (Appendix Table 7 , available at www.annals.org) (12, (35) (36) (37) (38) (39) (40) (41) . Many patients had acute leukemia or were having HPCT; however, patients with renal failure, critically ill patients, and others were included. Overall bleeding complication rates were low, ranging from 0% to 9% of catheter placements. The largest series of nontunneled CVC placements included 604 cannulations in 193 consecutive patients (41). In multivariate analysis, only patients with preprocedure platelet counts less than 20 × 10 9 cells/L (n = 93) were at increased risk for bleeding compared with patients with platelet counts greater than 100 × 10 9 cells/L. Ninety-six percent of bleeding events were grade 1, and the remaining 4% of bleeding events were grade 2, requiring only local compression. In another single-center study, bleeding outcomes were reported on 3170 tunneled CVCs placed under ultrasonography guidance in 2512 patients (38) . No bleeding complications occurred in the 344 CVC placements performed with a preprocedure platelet count less than 50 × 10 9 cells/L, including 42 cases with a platelet count less than 25 × 10 9 cells/L. Data from 7 observational studies of children or adults who were thrombocytopenic and had diagnostic or therapeutic lumbar puncture (LP) were evaluated (Appendix Table 8 
Rationale for Recommendations
Serious bleeding complications after CVC placement are rare, and when they occur, they are often unrelated to the platelet count (such as accidental arterial puncture). In aggregate, the existing data support the use of a 20 × 10 9 -cells/L platelet count threshold for CVC placement. The reported studies included patients with a wide range of primary diagnoses; this recommendation is intended to be broadly applicable to adult patients with hypoproliferative thrombocytopenia. Bleeding complications are rare with LPs, but hemorrhage anywhere in the central nervous system has the potential to cause devastating neurologic sequelae. In the absence of better published data supporting the safety of a lower threshold in adult patients, a fairly liberal platelet count threshold for LPs (that is, 50 × 10 9 cells/L) seems prudent. The 50 × 10 9 -cells/L threshold is intended for simple diagnostic or therapeutic LPs only. Despite a lack of supportive data, a greater platelet count is often recommended for other procedures, such as epidural anesthesia (50, 51).
Clinical Setting 3: Adult Patients Having Major Elective Nonneuraxial Surgery
Recommendations
Recommendation 4: The AABB suggests prophylactic platelet transfusion for patients having major CLINICAL GUIDELINE Platelet Transfusion: A Clinical Practice Guideline From the AABB elective nonneuraxial surgery with a platelet count less than 50 × 10 9 cells/L. Quality of evidence: very low; strength of recommendation: weak.
Recommendation 5: The AABB recommends against routine prophylactic platelet transfusion for patients who are nonthrombocytopenic and have cardiac surgery with cardiopulmonary bypass (CPB). The AABB suggests platelet transfusion for patients having CPB who exhibit perioperative bleeding with thrombocytopenia and/or with evidence of platelet dysfunction.
Quality of evidence: very low; strength of recommendation: weak.
Evidence Summary
In 1 series (Appendix Table 9 , available at www .annals.org) (52), 95 patients with acute leukemia and thrombocytopenia had 167 invasive procedures, including 29 major surgeries (such as thoracotomy) and 24 moderately invasive procedures (such as arteriovenous fistula construction). Platelet prophylaxis was given before the 130 procedures in which the preoperative platelet count was less than 50 × 10 9 cells/L. The median postoperative platelet count in these cases was 56 × 10 9 cells/L. Intraoperative blood loss greater than 500 mL occurred in only 7% of all operations, and there were no deaths due to bleeding. Preoperative platelet count was not significantly associated with intraoperative or postoperative bleeding.
In a meta-analysis of 6 RCTs and a single pilot study conducted during the licensure of aprotinin, adverse outcome data were compared between cardiac surgical patients who received (n = 284) or did not receive (n = 1436) perioperative platelet transfusions (Appendix Table 10 , available at www.annals.org) (53). Platelet transfusion was identified as an independent predictor of adverse outcomes, including mortality (OR, 4.76 [CI, 1.65 to 13.73]). It is possible that platelet transfusion served at least in part as a surrogate marker of sicker patients in this analysis, rather than as a direct cause of adverse outcomes (that is, confounding by indication).
Rationale for Recommendations
The consensus opinion of the panel is that platelet counts of 50 × 10 9 cells/L and greater are safe for major nonneuraxial surgery. There is no evidence of increased perioperative bleeding risk in thrombocytopenic patients with platelet counts greater than 50 × 10 9 cells/L. We recommend that platelet transfusion be withheld in nonbleeding surgical patients when the platelet count is greater than 50 × 10 9 cells/L and there is no evidence of coagulopathy. In contrast, we suggest that platelet transfusion should be considered in cardiac surgical patients with perioperative bleeding and thrombocytopenia (see the Definitions section) and/or suspected qualitative platelet abnormalities, which often result from exposure of platelets to the CPB circuit (54). Platelet transfusions are often administered to nonbleeding cardiac surgical patients (55). There are no data supporting this practice, and it should be discouraged.
Clinical Setting 4: Adult Patients Receiving Antiplatelet Therapy Who Have Intracranial Hemorrhage (Traumatic or Spontaneous)
Recommendations
Recommendation 6: The AABB cannot recommend for or against platelet transfusion for patients receiving antiplatelet therapy who have intracranial hemorrhage (traumatic or spontaneous).
Quality of evidence: very low; strength of recommendation: uncertain.
Evidence Summary
Five observational studies (n = 635) examined clinical outcomes among patients receiving antiplatelet agents who present with traumatic brain injury (Appendix Table 11 , available at www.annals.org) (56). One study reported a greater mortality rate for patients who received transfusions with platelets (relative risk, 2.4 [CI, 1.2 to 4.9]) (57), and a second study reported a lower mortality rate for patients receiving platelets (relative risk, 0.21 [CI, 0.05 to 0.95]) (58). Three studies showed no significant effect on mortality rates when patients received transfusions with platelets (59 -61). One additional observational study (n = 88) reported that patients with traumatic brain injury and moderate thrombocytopenia (50 × 10 9 to 107 × 10 9 cells/L) who were transfused with platelets had poorer survival than those who were not transfused with platelets (62) . In all of these studies, it was not possible to establish a causal relationship between platelet transfusion and clinical outcomes, and confounding by indication was possible.
Rationale for Recommendations
In patients with intracerebral hemorrhage who are receiving antiplatelet agents, the decision to transfuse platelets requires an individual clinical decision based on various clinical factors, including the size of the bleeding and the patient's level of consciousness. For surgeries involving the central nervous system, platelets are conventionally transfused prophylactically for a preprocedure platelet count less than 80 × 10 9 to 100 × 10 9 cells/L, although only low-quality data supporting this threshold are available.
DISCUSSION
A large proportion of platelet transfusions are administered prophylactically to reduce the risk for spontaneous hemorrhage in patients receiving chemotherapy or HPCT (1-3). With data available from severalbocytopenia. We recommend that these patients receive prophylactic platelet transfusions for a morning platelet count of 10 × 10 9 cells/L or less. Clinicians can be assured that prophylaxis with low-dose platelets provides hemostasis that is equal to standard-or highdose platelets in patients with therapy-induced hypoproliferative thrombocytopenia. However, low-dose platelets must be transfused more often because they provide a lower platelet increment (18) .
Only limited data are available to support transfusing platelets for indications other than prophylaxis against spontaneous bleeding in patients with therapyinduced hypoproliferative thrombocytopenia. Our panel took the position that it is appropriate for the AABB to address common and important clinical scenarios, such as the role of platelet transfusions in patients having invasive procedures, even as we await better data. Therefore, we decided to review observational data as a basis for platelet transfusion recommendations. The lower quality of data is reflected in the weak strength of recommendations outside of the hypoproliferative thrombocytopenia setting. In the specific case of CVC placement, our consensus opinion is that recent observational data (38, 41) support a platelet count transfusion threshold of 20 × 10 9 cells/L. This threshold seems to be reasonable even for the placement of large-bore catheters for apheresis in thrombocytopenic patients (12) . Observational data were also used to inform the platelet transfusion recommendation for LP, for which we suggest a threshold platelet count of 50 × 10 9 cells/L. Most of the published data about the safety of performing diagnostic LP in the setting of thrombocytopenia comes from a single center's experience with pediatric patients (45); it is unclear how generalizable these data are to adult patients. Of 21 case reports of LP-associated spinal hematomas in adults, 17 (81%) occurred at a platelet count less than 50 × 10 9 cells/L. However, in all but 1 patient, other risk factors for bleeding were identified (50). We believe that clinical judgment should be used about the need for platelet transfusion in patients requiring LP with platelet counts in the range of 20 × 10 9 to 50 × 10 9 cells/L.
Comparison With Other Published Guidelines
Our recommendation to provide prophylactic platelet transfusion at a platelet count of 10 × 10 9 cells/L or less for patients with therapy-induced hypoproliferative thrombocytopenia is consistent with the current standard of practice as reflected in other published transfusion guidelines (64 -70) . The recommendation of using a platelet count of 50 × 10 9 cells/L or greater as a safe level to perform LP in adults falls within the spectrum of other published guidelines, which have typically recommended platelet thresholds ranging from 20 × 10 9 to 50 × 10 9 cells/L (50, 65, 66) . The recommendation of a 50 × 10 9 -cells/L platelet transfusion threshold for major nonneuraxial procedures is also consistent with other guidelines (64 -70) . The suggestion to transfuse platelets to patients having CPB with perioperative bleeding and thrombocytopenia or suspected platelet dysfunction is concordant with the guideline from the Society of Thoracic Surgeons (71), which states, "It is reasonable to transfuse non-red cell hemostatic blood components based on clinical evidence of bleeding and preferably guided by specific point-of-care tests." We consider coronary artery bypass graft to serve as a model for all surgeries requiring CPB. Our recommendation to use a platelet count threshold of 20 × 10 9 cells/L for CVC placement represents the most substantial break from other published guidelines (64 -70, 72, 73) . The 2012 Society of Interventional Radiology guideline, for example, recommends a minimum platelet count of 50 × 10 9 cells/L for CVC placement (73) . We believe that existing observational data (38, 41) are sufficiently compelling to support using a lower platelet threshold. Adherence to this lower threshold should reduce transfusion risks while conserving resources.
Recommendations for Future Research
Grade 2 bleeding remains very common among patients receiving marrow-suppressive therapy, even with routine platelet prophylaxis (18, 19, 21) . Other means of preventing bleeding in this setting should be explored, such as using antifibrinolytic therapy. Serious or life-threatening bleeding (grade 3 or 4) is fortunately rare. When severe bleeding occurs in patients with therapy-induced hypoproliferative thrombocytopenia, it is often at a platelet count greater than the 10 × 10 9 -cells/L threshold typically used for prophylaxis (25). Future studies should explore the role of platelet prophylaxis in patient subgroups that may have specific risk factors for bleeding.
Data addressing the question of a minimum safe platelet count for performing invasive procedures are limited and observational in nature. Randomized trials of prophylactic platelet transfusion for procedures would be valuable but would present logistic and ethical challenges. However, it would be straightforward to establish registries to document the outcomes of consecutive patients having specific procedures. We believe that this should be a high research priority.
Platelet count is the main laboratory measurement used to guide platelet transfusion; however, it provides no qualitative information about platelet hemostatic function. The clinical utility of in vitro platelet hemostasis testing, particularly at the point of care, remains a key area of exploration.
The ideal approach to platelet transfusion would be to administer sufficient platelets to optimize patient outcomes while avoiding unnecessary transfusions with their attendant risks and costs. The recommendations in this guideline reflect the AABB's current thinking on how platelet transfusions should be used in various clinical settings. These recommendations are not meant to be interpreted as strict standards but should provide a useful adjunct to providers' clinical judgment as individualized transfusion decisions are being made. We anticipate that these guidelines will be refined and improved over time, using new data from welldesigned prospective trials. 7 . Additional search The yield on the original search strategy was not optimum for all diseases. Therefore, we also searched the Pubmed clinical queries by using a combination of 2 terms of "platelet transfusion" AND "disease category". 
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Manual search
The search strategy was supplemented by a manual search of references of the obtained full-text articles and existing guidelines in the field. In addition, we also contacted the members of the AABB Guidelines Panel to identify any unpublished articles or studies that were missed in the search. All obtained citations were entered into an EndNote database. In the first step, all duplicate citations were removed using the remove duplicate feature in the EndNote. Next, the abstract and title of all remaining citations were printed and manually reviewed for inclusion or exclusion by 2 reviewers according to the predetermined criteria. All the included studies were first sorted on the basis of study design and disease category. That is, in the first attempt, all reviewed studies were classified as randomized or observational; then, within the study design, all studies were collated according to the broad category of treatment vs. prophylactic followed by various disease categories (e.g., surgery, hematologic malignant tumors, and central venous catheter). All included observational studies within a disease category were classified as prospective observational or retrospective observational. For prospective observational cohort studies, we classified all studies as cohort studies either with comparison or without comparison. For retrospective observational studies, all studies were further classified as retrospective cohort with comparison or single-group or case series or case reports.
